Minocycline in Huntington's disease: A pilot study

Movement Disorders

Volumn 19, Issue 6, 2004, Pages 692-695

  Thomas, Madhavi ^a,c   Ashizawa, Tetsuo ^b   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Experimental Therapeutics Branch   (United States)

Author keywords

Apoptosis; Caspase inhibition; Huntington's disease; Minocycline; Neuroprotection

Indexed keywords

MINOCYCLINE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUNTINGTON CHOREA; LABORATORY DIAGNOSIS; MALE; MENTAL DISEASE; NAUSEA; NOSE DISEASE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RATING SCALE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; CASPASES; COGNITION DISORDERS; ENZYME INHIBITORS; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; MINOCYCLINE; NEUROPSYCHOLOGICAL TESTS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PILOT PROJECTS;

EID: 4444233214     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20018     Document Type: Article

References (25)

1. Jankovic J, Ashizawa T. Huntington's disease. In: Noseworthy J, editor. Neurologic therapeutics, principles and practice. London: Martin Dunitz Ltd.; 2003.
2. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
3. Jana NR, Zemskov EA, Wang GH, et al. Altered proteasomal function due to the expansion of polyglutamine expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome-c release. Hum Mol Genet 2001;10:1049-1059.
4. Chen M, Ona VO, Li M, Ferrante RJ, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington's disease. Nat Med 2000; 6:797-801.
5. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000;101:57-66.
6. Thomas M, Le W, Jankovic J. Minocycline and other tetracycline derivatives: A neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol 2003;26:18-23.
7. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
8. Marsden CD. Abnormal Involuntary Movements Scale (AIMS). Br J Clin Pharm 1981;11:129-151.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
10. Ryan M, Greenwald RA, Golub LM. Potential of tetracyclines to modify cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 1996;8:238-247.
11. Golub LM, Ramamurthy NS, Llavaneras A, et al. A chemically modified non-microbial tetracycline (CMT-8) inhibits gingival metalloproteinases, periodontal breakdown, and extra-oral bone loss in ovariectomized rats. Ann N Y Acad Sci 1999;878:290-310.
12. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002;13:1067-1070.
13. He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 2001;909:187-193.
14. Du Y, Ma Z, Lin S, Dodel RC, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:14669-14774.
15. Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum 1999;28:392-397.
16. Balestrero, S, Ciambelloti A, Parodi A, Rebora A. Minocycline-induced lupus-like syndrome. Int J Dermatol 2001;40:474-475.
17. Angulo JM, Sigal LH, Espinoza LR. Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Semin Arthritis Rheum 1998;28:187-192.
18. Masson C, Chevailler A, Pascaretti C, et al. Minocycline related lupus. J Rheumatol 1996;23:2160-2161.
19. Weese-Mayer DE, Yang RJ, Mayer JR, Zaparackas Z. Minocycline and pseudotumor cerebri: the well-known but well-kept secret. Pediatrics 2001;108:519-520.
20. O'Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001;44:2235-2241.
21. O'Dell JR, Paulsen G, Haire CE, et al. Treatment of early sero-positive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42:1691-1695.
22. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996;134: 693-695.
23. Bonelli RL, Heuberger C, Reisecker F. Minocycline for Huntington's disease: an open label study. Neurology 2003;60:883-884.
24. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 2003;53:267-270.
25. Smith DL, Woodman B, Mahal A, et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003;54:186-196.